Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model

Jesse Gore, Imade E. Imasuen-Williams, Abass M. Conteh, Kelly E. Craven, Monica Cheng, Murray Korc

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinomas (PDACs) are aggressive with frequent lymphatic spread. By analysis of data from The Cancer Genome Atlas, we determined that ~35% of PDACs have a pro-angiogenic gene signature. We now show that the same PDACs exhibit increased expression of lymphangiogenic genes and lymphatic endothelial cell (LEC) markers, and that LEC abundance in human PDACs correlates with endothelial cell microvessel density. Lymphangiogenic genes and LECs are also elevated in murine PDACs arising in the KRC (mutated Kras; deleted RB) and KIC (mutated Kras; deleted INK4a) genetic models. Moreover, pancreatic cancer cells (PCCs) derived from KRC tumors express and secrete high levels of lymphangiogenic factors, including the EGF receptor ligand, amphiregulin. Importantly, TGF-β1 increases lymphangiogenic genes and amphiregulin expression in KRC PCCs but not in murine PCCs that lack SMAD4, and combinatorial targeting of the TGF-β type I receptor (TβRI) with LY2157299 and EGFR/HER2 with lapatinib suppresses tumor growth and metastasis in a syngeneic orthotopic model, and attenuates tumor lymphangiogenesis and angiogenesis while reducing lymphangiogenic genes and amphiregulin and enhancing apoptosis. Therefore, this combination could be beneficial in PDACs with lymphangiogenic or angiogenic gene signatures.

Original languageEnglish (US)
Pages (from-to)143-153
Number of pages11
JournalCancer Letters
Volume379
Issue number1
DOIs
StatePublished - Aug 28 2016

Fingerprint

Lymphangiogenesis
Pancreatic Neoplasms
Adenocarcinoma
Neoplasm Metastasis
Endothelial Cells
LY-2157299
Genes
Neoplasms
Gene Expression
Atlases
Genetic Models
Microvessels
Cell Count
Genome
Apoptosis
Growth
Amphiregulin

Keywords

  • Lymphangiogenesis
  • Mouse model
  • Pancreatic cancer
  • TCGA
  • TGF-β

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gore, J., Imasuen-Williams, I. E., Conteh, A. M., Craven, K. E., Cheng, M., & Korc, M. (2016). Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. Cancer Letters, 379(1), 143-153. https://doi.org/10.1016/j.canlet.2016.05.037

Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. / Gore, Jesse; Imasuen-Williams, Imade E.; Conteh, Abass M.; Craven, Kelly E.; Cheng, Monica; Korc, Murray.

In: Cancer Letters, Vol. 379, No. 1, 28.08.2016, p. 143-153.

Research output: Contribution to journalArticle

Gore, J, Imasuen-Williams, IE, Conteh, AM, Craven, KE, Cheng, M & Korc, M 2016, 'Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model', Cancer Letters, vol. 379, no. 1, pp. 143-153. https://doi.org/10.1016/j.canlet.2016.05.037
Gore, Jesse ; Imasuen-Williams, Imade E. ; Conteh, Abass M. ; Craven, Kelly E. ; Cheng, Monica ; Korc, Murray. / Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. In: Cancer Letters. 2016 ; Vol. 379, No. 1. pp. 143-153.
@article{d2848b61feab41bda5f2a28678d2c09a,
title = "Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model",
abstract = "Pancreatic ductal adenocarcinomas (PDACs) are aggressive with frequent lymphatic spread. By analysis of data from The Cancer Genome Atlas, we determined that ~35{\%} of PDACs have a pro-angiogenic gene signature. We now show that the same PDACs exhibit increased expression of lymphangiogenic genes and lymphatic endothelial cell (LEC) markers, and that LEC abundance in human PDACs correlates with endothelial cell microvessel density. Lymphangiogenic genes and LECs are also elevated in murine PDACs arising in the KRC (mutated Kras; deleted RB) and KIC (mutated Kras; deleted INK4a) genetic models. Moreover, pancreatic cancer cells (PCCs) derived from KRC tumors express and secrete high levels of lymphangiogenic factors, including the EGF receptor ligand, amphiregulin. Importantly, TGF-β1 increases lymphangiogenic genes and amphiregulin expression in KRC PCCs but not in murine PCCs that lack SMAD4, and combinatorial targeting of the TGF-β type I receptor (TβRI) with LY2157299 and EGFR/HER2 with lapatinib suppresses tumor growth and metastasis in a syngeneic orthotopic model, and attenuates tumor lymphangiogenesis and angiogenesis while reducing lymphangiogenic genes and amphiregulin and enhancing apoptosis. Therefore, this combination could be beneficial in PDACs with lymphangiogenic or angiogenic gene signatures.",
keywords = "Lymphangiogenesis, Mouse model, Pancreatic cancer, TCGA, TGF-β",
author = "Jesse Gore and Imasuen-Williams, {Imade E.} and Conteh, {Abass M.} and Craven, {Kelly E.} and Monica Cheng and Murray Korc",
year = "2016",
month = "8",
day = "28",
doi = "10.1016/j.canlet.2016.05.037",
language = "English (US)",
volume = "379",
pages = "143--153",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model

AU - Gore, Jesse

AU - Imasuen-Williams, Imade E.

AU - Conteh, Abass M.

AU - Craven, Kelly E.

AU - Cheng, Monica

AU - Korc, Murray

PY - 2016/8/28

Y1 - 2016/8/28

N2 - Pancreatic ductal adenocarcinomas (PDACs) are aggressive with frequent lymphatic spread. By analysis of data from The Cancer Genome Atlas, we determined that ~35% of PDACs have a pro-angiogenic gene signature. We now show that the same PDACs exhibit increased expression of lymphangiogenic genes and lymphatic endothelial cell (LEC) markers, and that LEC abundance in human PDACs correlates with endothelial cell microvessel density. Lymphangiogenic genes and LECs are also elevated in murine PDACs arising in the KRC (mutated Kras; deleted RB) and KIC (mutated Kras; deleted INK4a) genetic models. Moreover, pancreatic cancer cells (PCCs) derived from KRC tumors express and secrete high levels of lymphangiogenic factors, including the EGF receptor ligand, amphiregulin. Importantly, TGF-β1 increases lymphangiogenic genes and amphiregulin expression in KRC PCCs but not in murine PCCs that lack SMAD4, and combinatorial targeting of the TGF-β type I receptor (TβRI) with LY2157299 and EGFR/HER2 with lapatinib suppresses tumor growth and metastasis in a syngeneic orthotopic model, and attenuates tumor lymphangiogenesis and angiogenesis while reducing lymphangiogenic genes and amphiregulin and enhancing apoptosis. Therefore, this combination could be beneficial in PDACs with lymphangiogenic or angiogenic gene signatures.

AB - Pancreatic ductal adenocarcinomas (PDACs) are aggressive with frequent lymphatic spread. By analysis of data from The Cancer Genome Atlas, we determined that ~35% of PDACs have a pro-angiogenic gene signature. We now show that the same PDACs exhibit increased expression of lymphangiogenic genes and lymphatic endothelial cell (LEC) markers, and that LEC abundance in human PDACs correlates with endothelial cell microvessel density. Lymphangiogenic genes and LECs are also elevated in murine PDACs arising in the KRC (mutated Kras; deleted RB) and KIC (mutated Kras; deleted INK4a) genetic models. Moreover, pancreatic cancer cells (PCCs) derived from KRC tumors express and secrete high levels of lymphangiogenic factors, including the EGF receptor ligand, amphiregulin. Importantly, TGF-β1 increases lymphangiogenic genes and amphiregulin expression in KRC PCCs but not in murine PCCs that lack SMAD4, and combinatorial targeting of the TGF-β type I receptor (TβRI) with LY2157299 and EGFR/HER2 with lapatinib suppresses tumor growth and metastasis in a syngeneic orthotopic model, and attenuates tumor lymphangiogenesis and angiogenesis while reducing lymphangiogenic genes and amphiregulin and enhancing apoptosis. Therefore, this combination could be beneficial in PDACs with lymphangiogenic or angiogenic gene signatures.

KW - Lymphangiogenesis

KW - Mouse model

KW - Pancreatic cancer

KW - TCGA

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=84973402341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973402341&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.05.037

DO - 10.1016/j.canlet.2016.05.037

M3 - Article

C2 - 27267807

AN - SCOPUS:84973402341

VL - 379

SP - 143

EP - 153

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -